XCRT Stock Overview
Acquires engineering/patents and applies to early-stage medical technology companies. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Xcelerate Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.028 |
| 52 Week High | US$0.06 |
| 52 Week Low | US$0.0071 |
| Beta | 3.11 |
| 11 Month Change | 69.70% |
| 3 Month Change | 53.85% |
| 1 Year Change | -37.78% |
| 33 Year Change | -64.56% |
| 5 Year Change | 2,700.00% |
| Change since IPO | -96.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| XCRT | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 221.8% | 1.6% | 2.2% |
| 1Y | -37.8% | 2.1% | 31.7% |
Return vs Industry: XCRT underperformed the US Healthcare industry which returned 2.9% over the past year.
Return vs Market: XCRT underperformed the US Market which returned 31.1% over the past year.
Price Volatility
| XCRT volatility | |
|---|---|
| XCRT Average Weekly Movement | 53.8% |
| Healthcare Industry Average Movement | 7.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: XCRT's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: XCRT's weekly volatility has increased from 36% to 54% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 12 | Michael O’Shea | www.xcelerate.global |
Xcelerate Inc. acquires engineering/patents and applies to early-stage medical technology companies. The company engages in the formulation, packaging and marketing of consumer health and beauty, and clinically tested skin care products; development of artificial intelligence and virtual health technology to assist patients; owning and licensing the rights to various forms of medical equipment. It also provides Ceramedx, a natural plant based therapeutic skin care product; Earth Science Beauty, which offers natural facial skincare targeted to specific skin types.
Xcelerate Inc. Fundamentals Summary
| XCRT fundamental statistics | |
|---|---|
| Market cap | US$9.95m |
| Earnings (TTM) | -US$1.35m |
| Revenue (TTM) | US$2.70m |
4.5x
P/S Ratio-9.0x
P/E RatioIs XCRT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XCRT income statement (TTM) | |
|---|---|
| Revenue | US$2.70m |
| Cost of Revenue | US$2.09m |
| Gross Profit | US$605.85k |
| Other Expenses | US$1.95m |
| Earnings | -US$1.35m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0031 |
| Gross Margin | 22.44% |
| Net Profit Margin | -49.82% |
| Debt/Equity Ratio | -259.6% |
How did XCRT perform over the long term?
See historical performance and comparison